Benzodiazepine use among young attendees of an Irish substance treatment center by Murphy, Kevin D. et al.
Title Benzodiazepine use among young attendees of an Irish substance
treatment center
Author(s) Murphy, Kevin D.; Byrne, Stephen; McCarthy, Suzanne; Lambert,
Sharon; Sahm, Laura J.
Publication date 2014-05
Original citation Murphy, K. D., Byrne, S., McCarthy, S., Lambert, S. and Sahm, L. J.
(2014) 'Benzodiazepine Use Among Young Attendees of an Irish
Substance Treatment Center', Journal of Addiction Medicine, 8(3), pp.
199-204. doi: 10.1097/ADM.0000000000000025
Type of publication Article (peer-reviewed)
Link to publisher's
version
https://journals.lww.com/journaladdictionmedicine/Fulltext/2014/05000/
Benzodiazepine_Use_Among_Young_Attendees_of_an.8.aspx
http://dx.doi.org/10.1097/ADM.0000000000000025
Access to the full text of the published version may require a
subscription.
Rights © 2014 American Society of Addiction Medicine. This is the
Accepted Manuscript version of a Published Work that appeared in
final form in Journal of Addiction Medicine, doi:
10.1097/ADM.0000000000000025
Item downloaded
from
http://hdl.handle.net/10468/6178
Downloaded on 2019-01-07T05:50:12Z
Journal of Addiction Medicine
 
Benzodiazepine use amongst young attendees of an Irish substance treatment centre
--Manuscript Draft--
 
Manuscript Number: JAM-D-13-00108R1
Full Title: Benzodiazepine use amongst young attendees of an Irish substance treatment centre
Short Title: Benzodiazepine use amongst young attendees of an Irish substance treatment centre
Article Type: Original Research
Keywords: Benzodiazepines, Ireland, young people, treatment centre
Corresponding Author: Kevin Daniel Murphy, BPharm
University College Cork
Cork, IRELAND
Corresponding Author Secondary
Information:
Corresponding Author's Institution: University College Cork
Corresponding Author's Secondary
Institution:
First Author: Kevin Daniel Murphy, BPharm
First Author Secondary Information:
Order of Authors: Kevin Daniel Murphy, BPharm
Suzanne McCarthy, PhD
Stephen Byrne, PhD
Sharon Lambert, PhD
Laura Jane Sahm, PhD
Order of Authors Secondary Information:
Manuscript Region of Origin: IRELAND
Abstract: Objective
To describe the demographic characteristics of those service-users attending Matt
Talbot Services, and their current and past substance use, and to explore the use of
benzodiazepines amongst this group.
Method
There were 198 service-users who attended a substance misuse treatment centre in
Cork, Ireland between January 2005 and August 2011.
Results
Benzodiazepines had ever been used by 51.0%, and of these, 55.8% were regular
benzodiazepine users. The mean age of first use was 14.9 ± 1.40 years. Regular users
of benzodiazepines were regular users of significantly more substances (3, IQR=2-3)
when compared with non-regular benzodiazepine users (1, IQR=1-2). Regular
benzodiazepine users showed more behavioural signs (12, IQR=10-14) than non-
regular users (9, IQR=7-12). Physical signs were significantly different between regular
(8, IQR=6-11) and non-regular (5, IQR=3-10) users.
Conclusions
The effects of benzodiazepine misuse affect the individual, their family, and society as
whole through hospitalisation, substance treatment and crime. Identifying regular
benzodiazepine users can help reduce the burden of benzodiazepines.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
 
 
~ 3 ~ 
 
Abstract 
Objective 
To describe the demographic characteristics of those service-users attending Matt Talbot Services, 
and their current and past substance use, and to explore the use of benzodiazepines amongst this 
group. 
Method 
There were 198 service-users who attended a substance misuse treatment centre in Cork, Ireland 
between January 2005 and August 2011.  
Results 
Benzodiazepines had ever been used by 51.0%, and of these, 55.8% were regular benzodiazepine 
users. The mean age of first use was 14.9 ± 1.40 years. Regular users of benzodiazepines were 
regular users of significantly more substances (3, IQR=2-3) when compared with non-regular 
benzodiazepine users (1, IQR=1-2). Regular benzodiazepine users showed more behavioural signs 
(12, IQR=10-14) than non-regular users (9, IQR=7-12). Physical signs were significantly different 
between regular (8, IQR=6-11) and non-regular (5, IQR=3-10) users.   
Conclusions 
The effects of benzodiazepine misuse affect the individual, their family, and society as whole 
through hospitalisation, substance treatment and crime. Identifying regular benzodiazepine users 
can help reduce the burden of benzodiazepines. 
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1. Introduction 
1.1. Background 
Treatment for substance misuse is a global issue. In 2010, there were between 3.1 and 7.2 million 
people who received treatment for substance dependence (UNODC, 2012). This is similar to the 
estimate of treatment uptake in 2005, which was around 3.7 million people (UNODC, 2007). It can 
be seen that there was little change in these numbers between these two periods. In Europe 
however, a different trend is observed as there has been a consistent rise in the number of people 
accessing drug treatment. In 2005 there were approximately 326,000 people attending drug 
treatment centres, but by 2010 this had increased by 45% (EMCDDA, 2007b, 2012a).  This increase 
has also been mirrored in first-time users of the treatment centres which showed that the numbers 
increased 38% to approximately 177,700 (EMCDDA, 2007a, 2012a).  Ireland has not been left 
untouched by this trend, with an approximate 35% increase in the number of cases handled by 
treatment centres in Ireland between 2005 and 2010 (Bellerose, Carew, & Lyons, 2011). In the same 
period of time, there was a 59% increase in the number of new persons entering into treatment. In 
2010, 9.3% of cases (equivalent to 707 people) related to those aged less than 18 years of age, which 
was a 75% increase in the number of adolescents in treatment in 2005. 
 Whilst international treatment service utilisation figures are not available nonetheless in Europe, 
there was a 94% increase in the number of under-25s accessing treatment between 2005 and 2010 
(EMCDDA, 2012b). Lifetime drug use amongst 15-34 years olds in Ireland has increased between 
2002 and 2011 by approximately 10% from 25.9% to 35.7% (National Advisory Committee on Drugs, 
2011). The most commonly used drugs in the year previous in this age group in 2010/2011 were 
alcohol (86.3%), tobacco (37.3%), opiates other than heroin [such as codeine, oxycodone and 
morphine] (28.3%), cannabis (10.3%), synthetic psychoactive substances (6.7%), and 
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sedatives/tranquilisers (4.8%). The sedative/tranquiliser category of drugs was the only category in 
which a rise was observed since the previous survey done in 2006/2007. In a recent review of 
substance use amongst young people, benzodiazepines were the only substance reviewed whose 
prevalence did not decrease over its 10-year review period (Murphy, Sahm, McCarthy et al., 2013). 
These two studies highlight that benzodiazepine misuse is not following the trend of decreasing use 
as other substances are. 
Progress has been made in reducing of the numbers of young people using benzodiazepines in 
Europe. Between 1995 and 2011, the percentage of 15/16 year olds that had used benzodiazepines 
without a prescription decreased from 7% (Bjorn Hibell, Andersson, Bjarnason et al., 1997) to 3% 
(Björn Hibell, Guttormsson, Ahlström et al., 2012), although this is greater than 2003 levels, 2% 
(Bjorn Hibell, Andersson, Bjarnason et al., 2004). This is in contrast to the percentage of young 
people who are prescribed benzodiazepines in Ireland which has decreased from 11% in 1999 (Bjorn 
Hibell, Andersson, Salme et al., 2000) to 9% in 2011 (Björn Hibell, Guttormsson, Ahlström, et al., 
2012). Combining these, it can be estimated that approximately 1-in-10 Irish 15/16 year olds use 
benzodiazepines. Another method of measuring benzodiazepine usage amongst young people in 
Ireland is to look at the number of young people entering treatment services in Ireland. Between 
2003 and 2008, there was a minimum of a 5-fold increase in the number of young people aged less 
than 18 years who received treatment for benzodiazepine use (Bellerose, Lyons, Carew et al., 2010). 
Benzodiazepines at therapeutic levels can have serious short-term side-effects, and chronic use can 
result in long-term consequences. Acute use of benzodiazepines can impair the perception of risk, 
which can lead to hazardous activities such as high-risk sexual behaviour and reckless driving 
(Dassanayake, Michie, Carter et al., 2011; Griffin, Kaye, Bueno et al., 2013). Benzodiazepines can also 
lead to paradoxical reactions such as restlessness, agitation, anxiety, aggressive behaviour, and 
delusions (Irish Medicines Board, 2011; Parsa, 2011). There is evidence that these paradoxical 
reactions are more likely to occur to those at either extremes of age i.e. a younger or older age 
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(Mancuso, Tanzi, & Gabay, 2004), and that combining with alcohol can increase the occurrence of 
violent behaviour (Forsyth, Khan, & McKinlay, 2011). Cognitive impairment is a well-documented 
side-effect of benzodiazepine use (M. J. Barker, K. M. Greenwood, M. Jackson et al., 2004; Boeuf-
Cazou, Bongue, Ansiau et al., 2011; Billioti de Gage, Begaud, Bazin et al., 2012), both short-term and 
long-term. There is evidence that these effects can remain even after treatment with 
benzodiazepines has ceased (Melinda J. Barker, Kenneth M. Greenwood, Martin Jackson et al., 2004; 
Stewart, 2005), although this is not without dispute (Verdoux, Lagnaoui, & Begaud, 2005). Although 
not directly related to benzodiazepines, it is also interesting to note in a National Office of Suicide 
Prevention report that benzodiazepines were the second leading method of self-harming in Ireland, 
after alcohol, in 2011, resulting in 3611 hospitalisations (National Suicide Research Foundation, 
2012). The significance of benzodiazepines in self-harm is such that the report views restricting 
access to benzodiazepines as a priority. 
1.2. Aims 
The aim of this paper is to characterise service-users who attend Matt Talbot Services (MTS) in the 
south of Ireland.  
Objective: 
 To describe the demographic characteristics of those service-users attending MTS, and their current 
and past substance use, and to explore the use of benzodiazepines amongst this group. 
2. Methods 
2.1. Design 
Ethical Approval for this research was gained from the Clinical Research Ethics Committee of the 
Cork Teaching Hospitals. The study used data collected from service-users who entered treatment 
with MTS between 2005 and August 2011. Applicants were initially interviewed by MTS staff to 
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identify those who would benefit from treatment. Those who passed the initial screening were 
accepted for treatment, while those not accepted were referred to alternatively-tiered services that 
could provide more appropriate treatment. A description of the 4-tier structure of mental health 
services is available elsewhere (Corrigan & O' Gorman, 2007). A total of 198 patient files were used 
in the study. Assessment was aided by the use of assessment forms. One of the forms included a 
section on the physical and behavioural impact of substance use. This was made up of 16 common 
behavioural symptoms and 12 physical signs of substance misuse. Service-users were asked to 
indicate if they had experienced any of these because of their substance misuse. 
2.2. Analyses 
Descriptive analysis of demographic data was done to provide a background of the service-user 
population type. Further descriptive analysis was performed on data relating to recent substance 
use, and examined by age and year of access to treatment.  Regular benzodiazepine use was defined 
as benzodiazepine use in the previous month. This is a common measure of current use in the 
substance misuse field (National Advisory Committee on Drugs, 2011; European Monitoring Centre 
for Drugs and Drug Addiction, 2006). For the comparison of regular benzodiazepine users and non-
regular benzodiazepine users, an independent t-test was performed on normally-distributed data, 
while the Mann-Whitney U test was performed on non-normally-distributed continuous/interval 
data. For nominal data, Pearson’s chi-square analysis was performed (with Yate’s continuity 
correction for 2x2 tables), and where expected values fell below 1 (or 5 for 2x2 tables), Fisher’s Exact 
Test was used instead. A significance level of α=0.05 was used for any inferential statistics 
calculated. All statistical analyses were performed using Predictive Analytics SoftWare Statistics 
(PASW; SPSS Inc. Chicago, Ill.) version 18.0. 
3. Results 
3.1 Demographic data 
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There were 198 service-users included in this study. Because of the number of incomplete forms, the 
sample numbers will vary between statistics; sample numbers are provided for each statistic 
reported. 
97.9% (n=185) of service-users were male. The age of service-users that had details (n=163) ranged 
from 13-21 and their mean age was 16.4 years with a standard deviation (SD) of 1.25 years. Referral 
to the service has increased from two in 2005 up to 49 in 2010, with 29 service-users accessing 
treatment up to August 2011, as can be seen in Figure 1.  
A breakdown of referral sources can be seen in Table 1. Juvenile Liaison officers (JLOs) were 
responsible for the most referrals (24.5%), while family members were the second largest group of 
referrals at 18.6%. Combining the referrals from JLOs and Probation officers, it can be seen that the 
Department of Justice is responsible for nearly half of all referrals (48.7%), whereas referrals from 
Department of Social Protection workers (social workers and youth centres) accounted for only 
20.3% of total referrals. 
Of the service-users who answered (n=184), 98.9% had ever consumed an alcoholic drink (See Table 
2). The median age of first consumption was 13 years (IQR=12-14.75). Cannabis and tobacco 
followed closely with lifetime use at 93.9% and 92.7% respectively. Cocaine and benzodiazepines 
were the only remaining substances that had lifetime use levels over 50% (54.3% and 51.0% 
respectively). 
3.2 Benzodiazepine use 
Benzodiazepines had ever been used by 80/157 of the service-users. Of these, 43 (55.8%) service-
users used benzodiazepines in the previous month, a measure of regular use (3 service-users did not 
answer the question). Daily use was recorded by 9 service-users, 19 service-users used 
benzodiazepines 2-6 times a week, and use of once a week or less was recorded for 15 service-users. 
The average age of first benzodiazepine use was 14.9 ± 1.40 years. 
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Characteristics of service-users entering treatment and their substance use history, as it relates to 
benzodiazepines, are examined in Table 3.                
A comparative examination of regular and non-regular users showed no significant difference in the 
age of first benzodiazepine use, as can be seen in Table 4. Regular users of benzodiazepines were 
regular users of significantly more substances (3, IQR=2-3) when compared with non-regular 
benzodiazepine users (1, IQR=1-2).  
Regular benzodiazepine users showed more behavioural signs (12, IQR=10-14) than non-regular 
users (9, IQR=7-12). Similarly, the physical signs were significantly different between regular (8, 
IQR=6-11) and non-regular (5, IQR=3-10) users. Both behavioural and physical signs were examined 
for differences between regular and non-regular users. Reporting of paranoia (p=0.018), loss of 
interest in sports and hobbies (p=0.039) and attention-seeking behaviour (p=0.022) were behaviours 
that differed significantly for regular and non-regular users. Pale/white skin (p=0.031) and vomiting 
(p=0.031) were the physical signs that were significantly different in both groups (See Error! 
Reference source not found.). 
                    
4. Discussion 
4.1. Summary 
This study examined the substance use history of a cohort of service-users attending an outpatient 
substance misuse treatment centre. An examination of these service-users’ background was also 
conducted. The majority of those attending the service were male and the mean age was 16.4 years. 
The biggest source of referrals from this cohort was from Juvenile Liaison Officers, which accounted 
for approximately a third of all referrals. Alcohol, cannabis, and tobacco were all experimented by 
over 90% of attendees. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 
~ 10 ~ 
 
Benzodiazepines had been experimented on by over half of the attendees, while over a quarter of 
attendees use benzodiazepines more than once a month, and the mean age of first benzodiazepine 
use was 14.9 years. A comparison of regular benzodiazepine users and non-regular benzodiazepine 
users showed that regular users experienced more behavioural symptoms. Paranoia, attention-
seeking behaviour, and loss of interest in sports were shown to occur more in regular 
benzodiazepine users. Regular users also reported more physical symptoms, with pallor and 
vomiting being significantly more common in regular users.  
There is a large discrepancy between the number of males and females that attended the treatment 
centre. The majority of service-users in treatment centres are generally male, and this can be seen in 
many other studies (Che, Assanangkornchai, McNeil et al., 2011). The overwhelming majority of 
attendees were male in this study (97.9%), and this is partially due to the aforementioned bias. 
However another cause must be factored in which is the mission statement of MTS was to help 
males that had substance dependence issues. Unofficially, they would accept females in crisis 
situations, so this kept the number of female clients lower than would be expected. This policy was 
changed in 2010 to accept both males and females. Regular admission of females should bring the 
gender ratio back in line with the studies shown above. 
Delusions such as paranoia can be known to occur with benzodiazepine use and this effect is classed 
in a category known as paradoxical reactions (Irish Medicines Board, 2011). The Summary of Product 
Characteristics (SPC) for Valium states that delusions occur in response to using benzodiazepines 
predominantly in the elderly and in children (Irish Medicines Board, 2011). Attention-seeking 
behaviour is often a symptom of borderline personality disorder (Aviram, Brodsky, & Stanley, 2006) 
and histrionic disorder (Bakkevig & Karterud, 2010). Both of these disorders have been associated 
with benzodiazepine dependence, possibly because they are prone to depression and anxiety 
(Konopka, Pełka-Wysiecka, Grzywacz et al., 2013).The loss of interest in sport may be related to 
effects of benzodiazepines. It is a common effect of regular substance use; it is listed as one of the 
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criteria for substance dependence in the Tenth Revision of the International Statistical Classification 
of Diseases and Related Health Problems (World Health Organisation, 1992). Specifically for 
benzodiazepines, if they are taken at clinical doses can lead to fatigue, drowsiness, decreased 
alertness, and depression (Irish Medicines Board, 2011). All of these side effects can lead to a 
decreased motivation which can result in decreased time spent on sports and hobbies. 
Skin pallor in benzodiazepine use is related to benzodiazepine withdrawal and can last weeks after 
withdrawal (Lader, 2011). There does not appear to be a link benzodiazepine use and vomiting 
according to SPCs. There was a weak link in the literature that described benzodiazepines as a 
potential anti-emetic (Yeo, Jung, Ryu et al., 2009). This suggests that vomiting may be a 
benzodiazepine withdrawal symptom, and there are cases reports that would support this 
hypothesis (Lin, Ma, & Liu, 2013), as well as evidence from primate research (Sannerud, Alien, Cook 
et al., 1991), and reviews (Dickinson, Rush, & Radcliffe, 1990). 
Looking more generally at negative behavioural and physical symptoms, regular benzodiazepine 
users experienced more behavioural and physical effects than non-regular users. This is to be 
expected as regular users will have more problems than others, however it is surprising that regular 
users experienced a wider spectrum of symptoms. In the case of physical symptoms, the difference 
is greater than 50%. It would be difficult to explain this discrepancy alone by increased 
benzodiazepine use; that would more likely lead to increased occurrence of similar symptoms. One 
possible factor that could influence this result was the difference between the numbers of regular 
medicines used by both groups of benzodiazepine users. Polysubstance use could account for a 
portion of the extra symptoms experienced by regular benzodiazepine users. 
 
4.2. Limitations 
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This study was cross-sectional in design. The ability to generalise these data to other substance 
misuse centres should be done cautiously. This is a retrospective study so the researchers had no 
control over the design of the forms used by the staff at the MTS.  This would have been 
advantageous as it would have been possible to customise the form so that a more thorough data 
could have been derived from it. Including further information on psychosocial and physical 
symptoms could provide a clearer picture of the experiences of these service-users. More 
information about the service-users’ family history and their interests may help give researchers a 
better perspective on how their substance misuse fits in their lives. 
This study surveyed adolescent service-users attending a substance misuse treatment centre. This is 
a specialised population that is not comparable to the general population. The level of drug use will 
be substantially higher among this population that among the population of adolescents in Ireland. 
Another factor that limits its generalisability to the general population is that the population is 
predominantly male. It has been mentioned previously that this is the case in other treatment 
centres internationally and may allow for comparison with other treatment centres. 
5. Conclusions 
This study presents data on the use of benzodiazepines among Irish adolescents attending a drug 
treatment centre. It is important that awareness about the level and severity of adolescent use of 
benzodiazepines is disseminated throughout the community, in particular among healthcare 
professionals. Benzodiazepines are powerful prescription medications used for a wide range of 
indications, including anxiety, insomnia, and epilepsy. Half of those who had taken benzodiazepines 
in this study became regular users. Recreational use of benzodiazepines can have acute and chronic 
effects, especially in a formative stage of life such as adolescence. Paranoia, attention-seeking 
behaviour, loss of interest in sports, pallor, and vomiting could indicate regular benzodiazepine use. 
Regular benzodiazepine users often are polysubstance users and the risks of mixing substances 
should be known. The effects of benzodiazepine misuse affect the individual, their family, and 
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society as whole through hospitalisation, substance treatment and crime. Identifying regular 
benzodiazepine users can help reduce the burden of benzodiazepines. 
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Table 1.Breakdown of referrals of service users by source of referral (n=113) 
Referral source % of total referrals (n) 
Juvenile Liaison Officer 34.5 (39) 
Family 18.6 (21) 
Social Worker 16.8 (19) 
Probation officer 14.2 (16) 
Other 5.3 (6) 
Self 3.5 (4) 
Youth Centre 3.5 (4) 
School 2.7 (3) 
Other Treatment Centre 0.9 (1) 
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Table 2. Service-users that have ever used a substance 
Substance % ever used (n) 
Alcohol 98.9 (182) 
Cannabis 93.9 (170) 
Tobacco 92.7 (153) 
Cocaine 54.3 (88) 
Benzodiazepines 51.0 (80) 
Ecstasy 49.4 (80) 
Petrol 34.2 (53) 
Amphetamines 28.8 (44) 
Head shop 51.4 (37) 
Mushrooms 18.5 (28) 
Lysergic acid (LSD) 11.8 (18) 
Opiates 3.4 (5) 
Heroin 50.0 (1) 
 
 
 
 
 
  
 
 
 
 
Table 3. Comparison of service-user characteristics of regular and non-regular benzodiazepine users 
Measure Regular users Non-regular users Significance 
Mean age ± S.D. (years) 16.6 ± 1.02 16.7 ±1.20 t=0.585, p=0.561 
Gender 
     Male (%) 
     Female (%) 
 
97.5 
  2.5 
 
100.0 
  0.0 
 
p=1.000 
Source of referral 
     Juvenile Liaison Officer (%) 
     Probation and Welfare Officer (%) 
     Social Worker (%) 
     Other (%) 
     Family (%) 
     Youth Centre (%) 
     Self (%) 
 
30.0 
15.0 
10.0 
 10.0 
25.0 
10.0 
  0.0 
 
28.6 
21.4 
21.4 
  0.0 
14.3 
  7.1 
  7.1 
 
 
 
p=0.776 
Median substances ever used 
Median substances used in the previous month 
Mean age of first benzodiazepine use 
  7 
  3 
14.8 
  7 
  1 
15.2 
Z=-1.750, p=0.080 
Z=-5.096, p<0.001* 
t=-1.105, p=0.269 
                  * signifies significance ≤ 0.05 
 
 
 
 Table 4. Comparison of physical and behavioural symptoms experienced by benzodiazepine users 
Measure Regular 
users 
Non-
regular 
Significance Total, % 
(n) 
Median behavioural symptoms 12   9 Z=-2.434, p=0.015*  
Behavioural symptoms 
     Alcohol or prescription drugs going missing or dwindling in the house 
     Changing friends and moving away from old friends 
     Dramatic attention-seeking behaviour 
     Extreme apathy 
     Hyperactivity 
     Impulsive behaviour 
     Increased irritability 
     Increased time spent alone in room/withdrawn behaviour 
     Loss of interest in sports and hobbies 
     Low mood 
     Money/objects missing from home that could be easily converted                     
into cash 
     Paranoia 
     Relationships with peers/siblings/parents affected 
     Suicidal ideation 
     Suicide attempts 
     Temper outbursts 
 
69.4% 
79.5% 
81.3% 
80.6% 
83.8% 
94.7% 
89.7% 
88.9% 
97.3% 
87.2% 
66.7% 
 
94.9% 
94.4% 
35.1% 
22.9% 
92.3% 
 
55.2% 
72.4% 
50.0% 
60.7% 
76.7% 
83.3% 
74.2% 
69.0% 
80.0% 
73.3% 
55.2% 
 
74.2% 
80.8% 
31.0% 
20.7% 
80.0% 
 
χ²=0.859, p=0.354 
χ²=0.153, p=0.696 
χ²=5.232, p=0.022* 
χ²=1.960, p=0.161 
χ²=0.178, p=0.673 
p=0.227 
χ²=1.947, p=0.163 
χ²=2.837, p=0.092 
p=0.039 
χ²=1.317, p=0.251 
χ²=0.477, p=0.490 
 
p=0.018* 
p=0.119 
χ²=0.008, p=0.930 
χ²=0.000, p=1.000 
p=0.163 
 
47.7 (73) 
68.9 (111) 
65.2 (101) 
60.0 (87) 
67.7 (109) 
79.6 (129) 
78.9 (131) 
63.3 (100) 
76.8 (129) 
70.4 (114) 
48.4 (74) 
 
72.0 (116) 
79.7 (122) 
28.0 (44) 
15.7 (24) 
79.8 (134) 
Median physical signs 8 6 Z=-1.969, p=0.049*  
Measure Regular 
users 
Non-
regular 
Significance Total, % 
(n) 
Physical signs 
     Blackouts 
     Bloodshot eyes that appear glassy or vague 
     Change in appetite 
     Change in weight 
     Deterioration in appearance 
     Excessive sleeping 
     Insomnia 
     Loss of fine motor co-ordination e.g. holding a glass 
     Short-term memory loss 
     Vomiting or flushed complexion 
     White or pale face 
 
83.8% 
85.7% 
86.1% 
81.6% 
74.3% 
59.5% 
79.5% 
75.0% 
91.7% 
71.4% 
86.8% 
 
83.3% 
71.4% 
67.9% 
60.0% 
48.3% 
55.6% 
60.7% 
60.7% 
93.1% 
40.7% 
60.7% 
 
p=1.000 
χ²=1.164, p=0.281 
χ²=2.096, p=0.148 
χ²=2.880, p=0.090 
χ²=3.535, p=0.060 
χ²=0.003, p=0.955 
χ²=1.979, p=0.160 
χ²=0.905, p=0.341 
p=1.000 
χ²=4.702, p=0.030* 
χ²=4.654, p=0.031* 
 
71.4 (115) 
61.3 (93) 
61.3 (95) 
62.0 (103) 
54.8 (86) 
49.0 (77) 
59.9 (97) 
46.5 (72) 
69.2 (108) 
44.1 (67) 
65.9 (108) 
* signifies significance ≤ 0.05 
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